Translational tidbits

At least $440 million in new support for public-private partnerships was allocated last month globally. Almost $230 million of that amount is earmarked for the NIH's Accelerating Medicines Partnership¹ (see "Selected public-private partnerships for February 2014").

Accelerating Medicines Partnership members will collaborate on projects to identify and validate disease targets in Alzheimer's disease (AD), type 2 diabetes, rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Over the public-private partnership's 5-year run, the NIH will provide $118.9 million in funding, and industry partners will provide the remaining $110.6 million in the form of funding and in-kind contributions...